Fritz Renner1, Arnoud Arntz2, Frenk P M L Peeters3, Jill Lobbestael4, Marcus J H Huibers5. 1. MRC Cognition and Brain Sciences Unit, Cambridge, United Kingdom; Department of Clinical Psychological Science, Maastricht University, The Netherlands. Electronic address: Fritz.Renner@mrc-cbu.cam.ac.uk. 2. Department of Clinical Psychological Science, Maastricht University, The Netherlands; Department of Clinical Psychology, University of Amsterdam, The Netherlands. 3. Department of Psychiatry and Neuropsychology, University Hospital Maastricht, The Netherlands. School for Mental Health and Neuroscience, Faculty of Health, Medicine and Life sciences, Maastricht University, The Netherlands. 4. Department of Clinical Psychological Science, Maastricht University, The Netherlands. 5. Department of Clinical Psychology, VU University Amsterdam, The Netherlands; Department of Clinical Psychological Science, Maastricht University, The Netherlands.
Abstract
BACKGROUND AND OBJECTIVES: The aim of this study was to test the effects of individual schema therapy (ST) for patients with chronic depression. METHODS: Using a multiple-baseline single case series design, patients with chronic major depressive disorder (N = 25) first entered a 6-24 weeks baseline phase; this phase functioned as a no-treatment control condition. Then, patients started a 12 week exploration phase during which symptoms and underlying schemas were explored; this phase functioned as an attention control condition. Next, patients received up to 65 sessions of individual ST. The Beck Depression Inventory II (BDI-II) and the Quick Inventory of Depressive Symptomatology (QIDS) were the primary outcome measures. The BDI-II was assessed once a week during all phases of the study resulting in 100 repeated assessments per participant on average. Mixed regression analysis was used to contrast change in symptoms during the intervention with change in symptoms during the baseline and exploration control phases. RESULTS: When compared to the no-treatment control period, the intervention had a significant, large effect on depressive symptoms (Cohen's d BDI-II = 1.30; Cohen's d QIDS = 1.22). Effects on secondary continuous outcomes were moderate to large. LIMITATIONS: The small sample size and lack of a control group. CONCLUSIONS: These findings provide evidence that ST might be an effective treatment for patients with chronic depression.
RCT Entities:
BACKGROUND AND OBJECTIVES: The aim of this study was to test the effects of individual schema therapy (ST) for patients with chronic depression. METHODS: Using a multiple-baseline single case series design, patients with chronic major depressive disorder (N = 25) first entered a 6-24 weeks baseline phase; this phase functioned as a no-treatment control condition. Then, patients started a 12 week exploration phase during which symptoms and underlying schemas were explored; this phase functioned as an attention control condition. Next, patients received up to 65 sessions of individual ST. The Beck Depression Inventory II (BDI-II) and the Quick Inventory of Depressive Symptomatology (QIDS) were the primary outcome measures. The BDI-II was assessed once a week during all phases of the study resulting in 100 repeated assessments per participant on average. Mixed regression analysis was used to contrast change in symptoms during the intervention with change in symptoms during the baseline and exploration control phases. RESULTS: When compared to the no-treatment control period, the intervention had a significant, large effect on depressive symptoms (Cohen's d BDI-II = 1.30; Cohen's d QIDS = 1.22). Effects on secondary continuous outcomes were moderate to large. LIMITATIONS: The small sample size and lack of a control group. CONCLUSIONS: These findings provide evidence that ST might be an effective treatment for patients with chronic depression.
Authors: Marit Kool; Henricus L Van; Anna Bartak; Saskia C M de Maat; Arnoud Arntz; Johanna W van den Eshof; Jaap Peen; Matthijs Blankers; Judith E Bosmans; Jack J M Dekker Journal: BMC Psychiatry Date: 2018-08-07 Impact factor: 3.630
Authors: Johannes Kopf-Beck; Petra Zimmermann; Samy Egli; Martin Rein; Nils Kappelmann; Julia Fietz; Jeanette Tamm; Katharina Rek; Susanne Lucae; Anna-Katharine Brem; Philipp Sämann; Leonhard Schilbach; Martin E Keck Journal: BMC Psychiatry Date: 2020-10-14 Impact factor: 3.630